多肽药物生物样品分析方法选择的考量  

Considerations of the analytical method selection for biological samples of peptide drug

作　　者：翟建平 董立厚 向慎思 李黎 葛志强[1] ZHAI Jian-ping;DONG Li-hou;XIANG Shen-si;LI Li;GE Zhi-qiang(School of Chemical Engineering,Tianjin University,Tianjin 300072,China;Institute of Lifeomics,Academy of Military Medical Science,Military Academy of Sciences,Beijing 102206,China)

机构地区：[1]天津大学化工学院,天津300072 [2]军事科学院军事医学研究院生命组学研究所,北京102206

出　　处：《中国新药杂志》2020年第11期1245-1250,共6页Chinese Journal of New Drugs

基　　金：国家“重大新药创制”科技重大专项资助项目(2020ZX09201026)。

摘　　要：多肽药物具有靶点明确、成药性好等优点,现今已成为新药研究的热点之一。多肽药物具有给药剂量低、结构与内源性多肽高度相似等特点,因此多肽药物在生物样品分析中面临着诸多挑战,尤其在灵敏度和选择性等方面。本文收集整理了近年来已上市或在研多肽药物的生物样品分析方法,为后续研究者在选择其分析方法时提供参考。Peptide drugs have the advantages of clear target and good drugability,which have become one of the hotspots in new drug research.Peptide drugs are characteristic of low effective dose and high similarity in structures to endogenous polypeptide.Therefore,peptide drugs are facing many challenges in the analysis of its biological samples,especially in terms of sensitivity and selectivity.This review collects and analyzes the analysis methods for the determination of biological samples that have been marketed or researched in recent years,and provides a reference for subsequent researchers to select appropriate bioanalytical method for peptide drugs.

关 键 词：多肽药物 生物样品分析 液相色谱-串联质谱法 配体结合分析法 

分 类 号：R972.6[医药卫生—药品]